APPLY NOW

 

 

Applications to our PhD positions are now closed. Thank you very much to all applicants!

We are looking forward to having our 12 early stage researchers starting their projects!

 

WHAT IS INTERCEPT-MDS?

EXPLORING CELL-TO-CELL HETEROGENEITY AND EXPLOITING EPIGENETIC REGULATION FOR THE INTERCEPTION OF MYELOID DISEASE CELLS

INTERCEPT-MDS brings together 10 European public and private institutions in a European network of experts in leukaemia, epigenetics and single-cell technology.

Through a multidisciplinary and multisectoral approach, our aim is to train Europe’s first experts in the novel field of disease interception: treating a disease before it fully develops by removing altered cells.

SCIENTIFIC EXCELLENCE AND PERSONAL DEVELOPMENT

The highly complementary composition of the INTERCEPT-MDS network will provide all the key expertise and infrastructure to support the scientific excellence of our PhD candidates.

Experts from two sectors (academia and industry) and two research environments (clinical and basic) across Europe will offer a unique multidisciplinary and multisectoral training opportunity in the novel field of disease interception.

Successful applicants will be enrolled in a PhD programme and will receive a structured training programme consisting of soft skill courses, targeted workshops, conferences, retreats, social events and networking.

In addition, our PhD candidates will carry out secondments in other European institutions within the network to provide the needed interactions to achieve research and training excellence, and improve their future career perspectives in academia and the private sector.